MedTrace Logo

Iparomlimab and Tuvonralimab (QL1706) in Patients With HR-positive, HER2-negative Advanced Breast Cancer

NCT07180160 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 123

Last updated 2025-11-18

No results posted yet for this study

Summary

This is a prospective, randomised, controlled, multicentre study to evaluate the efficacy and safety of Iparomlimab and Tuvonralimab (QL1706) in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer.

Conditions

Interventions

DRUG

Fulvestrant

SERD

DRUG

QL1706

QL1706 is a single bifunctional MabPair product consisting of two engineered monoclonal antibodies (anti-PD-1 and anti-CTLA-4).

DRUG

CDK4/6 inhibitor

palbociclib OR ribociclib OR abemaciclib OR dalpiciclib

Sponsors & Collaborators

  • Wenjin Yin

    lead OTHER

Principal Investigators

  • Wenjin Yin, M.D. · Renji Hospital,School of Medicine, Shanghai Jiaotong University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-25
Primary Completion
2027-09-30
Completion
2028-03-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07180160 on ClinicalTrials.gov